HIGHLIGHTS
- who: Sarah P. Blagden from the consequences for clinical research in the UKUniversity of have published the research work: Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective, in the Journal: (JOURNAL) of 29/09/2022
- what: Despite the horror and tragedy of the COVID-19 pandemic, the clinical research community has gained important insights into how CID studies can be run rapidly and at scale.
- future: Protocol Development Seek to include all possible future modifications (e_g additional study arms) to reduce need for any substantial amendments . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.